Latest stories on VBIO
Valion Bio (VBIO) Reports Positive Safety Study Results for Entolimod, Advancing ARS Treatment
GuruFocus64 · neutralproduct/pr
Valion Bio announces data from NIAID, RNCP-funded safety study of Entolimod
The Fly58 · neutralproduct/pr
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
StockTitan63 · neutralm&a
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
Valion Bio unveils agenda to accelerate clinical pipeline, shareholder value
The Fly58 · neutralproduct/pr
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
StockTitan63 · neutralproduct/pr
Valion Bio files to sell 3.95M shares of common stock for holders
The Fly28 · bearishgeneral
Valion, LarmorBio announces Velocity completed feasibility eval of BioScan-NMR
The Fly56 · neutralproduct/pr
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
StockTitan58 · neutralproduct/pr
Valion Bio highlights capabilities of Velocity Bioworks
The Fly56 · neutralproduct/pr
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
StockTitan64 · neutralproduct/pr
Valion Bio files $100M mixed securities shelf
The Fly48 · neutralgeneral
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
Valion Bio outlines perspectives of new Board Chair Jensen
The Fly50 · neutralgeneral
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
StockTitan56 · neutralgeneral
Valion Bio, Inc. (VBIO) files 8-K
SEC 8-K50 · neutralgeneral
VBIO Jumps as Valion Completes Needle-Free Oral Mucosal Entolimod Formulation
September 30, 2026
MarketChameleon63 · neutralproduct/pr
VBIO Highlights Needle-Free Entolimod Milestone, Pointing to a 10–40x Dose Opportunity Versus Injectable Plans
September 30, 2026
MarketChameleon63 · neutralproduct/pr